Announcement on Participating in the Investment in Shanghai Sansheng Pharmaceutical Private Equity Investment Fund Partnership (Limited Partnership)
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed in this announcement, and are jointly and severally liable for any false representations, misleading statements, or material omissions.
I. Overview of External Investment
Hangzhou Tigermed Technology Co., Ltd. (hereinafter referred to as "Tigermed" or "the Company") intends to participate in the investment in Shanghai Sansheng Pharmaceutical Private Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "the Partnership" or "the Fund") through Hangzhou Tigermed Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "the Investment Vehicle"). The Fund plans to initially subscribe for a total capital contribution of RMB 950 million. The Investment Vehicle will act as a limited partner (LP) in the Partnership and will subscribe for a capital contribution of RMB 200 million with its own funds.
The Investment Vehicle, Hangzhou Tigermed Equity Investment Partnership (Limited Partnership), was established on April 22, 2016. Its partnership interests are held by the Company and its wholly-owned subsidiary, serving as the Company's professional investment platform. It was jointly initiated by two partners, with Shanghai Tigermed Pharmaceutical Technology Co., Ltd. as the general partner and Hangzhou Tigermed Technology Co., Ltd. as the limited partner.
In accordance with the Company's articles of association and relevant regulations, this investment has been reviewed and approved by the first meeting of the sixth board of directors. This external investment does not constitute a related party transaction and does not fall under the definition of a major asset restructuring as stipulated in the "Administrative Measures for Major Asset Restructuring of Listed Companies." The funds for this investment will come from the Company's own capital.